The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
As of close of business last night, Guardant Health Inc’s stock clocked out at $48.60, up 2.97% from its previous closing price of $47.20. In other words, the price has increased by $2.97 from its previous closing price. On the day, 2.76 million shares were traded. GH stock price reached its highest trading level at $48.82 during the session, while it also had its lowest trading level at $45.42.
Ratios:
To gain a deeper understanding of GH’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.85 and its Current Ratio is at 6.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on Jan-24-25, initiated with a Overweight rating and assigned the stock a target price of $60.
On June 28, 2024, Guggenheim Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $36.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 17 ’25 when Tariq Musa sold 116 shares for $37.58 per share. The transaction valued at 4,359 led to the insider holds 2,944 shares of the business.
Tariq Musa bought 116 shares of GH for $4,359 on Jan 17 ’25. On Dec 18 ’24, another insider, Tariq Musa, who serves as the Director of the company, sold 116 shares for $34.85 each. As a result, the insider received 4,043 and left with 2,810 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 6004772864 and an Enterprise Value of 6313820160. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.67. Its current Enterprise Value per Revenue stands at 9.121 whereas that against EBITDA is -16.344.
Stock Price History:
The Beta on a monthly basis for GH is 1.35, which has changed by 1.0432901 over the last 52 weeks, in comparison to a change of 0.24440956 over the same period for the S&P500. Over the past 52 weeks, GH has reached a high of $49.86, while it has fallen to a 52-week low of $15.81. The 50-Day Moving Average of the stock is 40.98%, while the 200-Day Moving Average is calculated to be 76.23%.
Shares Statistics:
It appears that GH traded 2.05M shares on average per day over the past three months and 2933340 shares per day over the past ten days. A total of 123.16M shares are outstanding, with a floating share count of 117.73M. Insiders hold about 4.72% of the company’s shares, while institutions hold 103.01% stake in the company. Shares short for GH as of 1735603200 were 7794410 with a Short Ratio of 3.81, compared to 1732838400 on 9170557. Therefore, it implies a Short% of Shares Outstanding of 7794410 and a Short% of Float of 6.569999999999999.
Earnings Estimates
The stock of Guardant Health Inc (GH) is currently in the spotlight, with 13.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.4 and low estimates of -$0.74.
Analysts are recommending an EPS of between -$1.84 and -$2.95 for the fiscal current year, implying an average EPS of -$2.0. EPS for the following year is -$2.02, with 13.0 analysts recommending between -$1.52 and -$2.89.
Revenue Estimates
In the current quarter, 17 analysts expect revenue to total $190.7M. It ranges from a high estimate of $200M to a low estimate of $185.29M. As of the current estimate, Guardant Health Inc’s year-ago sales were $155.05MFor the next quarter, 17 analysts are estimating revenue of $190.74M. There is a high estimate of $201.37M for the next quarter, whereas the lowest estimate is $183M.
A total of 19 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $737.2M, while the lowest revenue estimate was $722.5M, resulting in an average revenue estimate of $726.74M. In the same quarter a year ago, actual revenue was $563.95MBased on 21 analysts’ estimates, the company’s revenue will be $851.24M in the next fiscal year. The high estimate is $922.7M and the low estimate is $816.3M.
